Business Wire

Merz Aesthetics ® Announces Salma Hayek Pinault as First-Ever Global Brand Ambassador for Ultherapy PRIME, the Next Generation Platform for Nonsurgical Skin Lifting and Tightening Treatments

9.4.2025 13:01:00 CEST | Business Wire | Press Release

Share

Merz Aesthetics®, the world’s largest dedicated medical aesthetics business, is proud to announce world-renowned actress, director and producer, Salma Hayek Pinault, as the first-ever global brand ambassador for Ultherapy PRIME.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250409655489/en/

Redefining the future in medical aesthetics, Ultherapy PRIME is an advanced micro-focused ultrasound platform for personalized, non-invasive skin lifting and tightening.1,2 It is intended to lift and sculpt the skin of the upper face, lower face, neck and décolleté.1 It takes just one session, has no downtime, and delivers results that can last up to a year or more.1-3

With her unwavering commitment to authenticity, Salma Hayek Pinault trusts Ultherapy PRIME for a personalized, natural-looking lift, with results that can last up to a year or more .1-3 This collaboration reflects a shared belief in empowering individuals to look and feel their best to fuel confidence worldwide.

Salma Hayek Pinault is a highly acclaimed, Academy Award-nominated actress and Emmy-winning director, also celebrated for her work as a producer. She passionately advocates for causes that align with her core values and beliefs and has long supported several leading nonprofit organizations. As a strong advocate for authentic self-expression and looking great at any age, she encourages others to embrace treatments that enhance their natural features.

“Self-care is essential. Years on screen have taught me to embrace my journey and seek treatments that enhance my natural beauty,” said Salma Hayek Pinault. “Ultherapy PRIME boosts my production of collagen and elastin exactly where I need it*, giving me a long-lasting**, natural-looking lift. It's noninvasive, takes only one session, and has zero downtime. It is the future of beauty, and that’s why I can't stop talking about it."1-3,6

The Ultherapy PRIME platform is the evolution of Ultherapy® which has been recognized as the Gold Standard in non-invasive skin lifting and tightening.2 Built on Ultherapy®’s legacy of proven, natural-looking results, Ultherapy PRIMEredefines the future of nonsurgical skin lifting and tightening by uniquely combining an advanced micro-focused ultrasound platform with vivid real-time imaging.1 These advancements promote a safer and more effective, personalized lift that can last up to a year or more, paired with younger-looking skin.1-5

Since its September 2024 launch, Ultherapy PRIME has already been cleared in over 80% of our targeted markets, with more approvals expected in 2025.***

"We are proud and excited about the recent launch of Ultherapy PRIME, our next-generation platform for non-invasive skin lifting and tightening and a testament to our unwavering commitment to delivering meaningful innovations to our customers," said Bob Rhatigan, CEO of Merz Aesthetics®. "As we continue to expand the global footprint of this launch, we are thrilled to collaborate with Salma Hayek Pinault as the first-ever global brand ambassador for Ultherapy PRIME. At Merz Aesthetics® we empower individuals to embrace their unique beauty with confidence, and our collaboration with Salma Hayek Pinault compellingly embodies this purpose.”

To learn more and find a provider near you, visit Ultherapy.com. Follow @Ultherapy on Instagram for the latest news from Ultherapy PRIME and Hayek Pinault.

About Merz Aesthetics®

Merz Aesthetics® is a medical aesthetics business with a long history of empowering health care professionals, patients, and employees to live every day with confidence. We aim to help people around the world look, feel and live like the best versions of themselves – however they define it. Clinically proven, its product portfolio includes injectables and devices designed to meet each patient’s needs Being family owned for more than 115 years, Merz Aesthetics® is known for building unique connections with customers who feel like family. Merz Aesthetics®’ global headquarters is in Raleigh, N.C., USA, with a commercial presence in 90 countries worldwide. It is also a part of Merz Group, which was founded in 1908 and is based in Frankfurt, Germany. Learn more at merzaesthetics.com.

About Ultherapy®

The noninvasive Ultherapy® procedure is intended for dermatological sculpting and lifting of the dermis on the upper face, lower face, neck and décolleté. The most common side effects reported in clinical trials were redness, swelling, pain and transient nerve effects. Reported adverse events from post-marketing surveillance are available in the Instructions for Use (IFU). Please see the IFU for product information.

* The exact skin depth targeting occurs due to real-time visualization

**lasts up to a year or more

***Ultherapy PRIME is currently unavailable in China, India, Azerbaijan, Russia, Costa Rica, Dominican Republic, Guatemala, Mexico, Peru, Uruguay, Iraq, Israel, Jordan, Lebanon

References:

  1. Ulthera® Instructions for Use.
  2. Fabi SG, Joseph J, Sevi J, Green JB, Peterson JD. Optimizing patient outcomes by customizing treatment with microfocused ultrasound with visualization: gold standard consensus guidelines from an expert panel. J Drugs Dermatol. 2019;18(5):426-432.
  3. Werschler WP, Werschler PS. Longterm efficacy of micro-focused ultrasound with visualization for lifting and tightening lax facial and neck skin using a customized vectoring treatment method. J Clin Aesthet Dermatol. 2016;9(2):27-33.
  4. Pavicic T, Ballard JR, Bykovskaya T, et al. Microfocused ultrasound with visualization: consensus on safety and review of energy-based devices. J Cosmet Dermatol. 2022;21(2):636-647.
  5. Goldie K, Kerscher M, Fabi SG, Hirano C, Landau M, Lim TS, Woolery-Lloyd H, Mariwalla K, Park JY, Yutskovskaya Y. Skin Quality - A Holistic 360° View: Consensus Results. Clin Cosmet Investig Dermatol. 2021 Jun 14;14:643-654. doi: 10.2147/CCID.S309374. PMID: 34163203; PMCID: PMC8214518.
  6. Marquardt K, Hartmann C, Wegener F, Park JY, Halbert D, Hsu S, Hengl T. Microfocused Ultrasound With Visualization Induces Remodeling of Collagen and Elastin Within the Skin. J Cosmet Dermatol. 2025 Jan;24(1):e16638

© 2025 Ulthera, Inc. All Rights Reserved. MERZ AESTHETICS® is a trademark and/or registered trademark of Merz Pharma GmbH & Co. KGaA in the U.S. and/or certain other countries. ULTHERA, ULTHERAPY, and ULTHERAPY PRIME are trademarks and/or registered trademarks of Ulthera, Inc. in the U.S. and/or certain other countries.

Various features of the ULTHERA® System are covered by U.S. patents identified at https://merzaesthetics.com/patents/. Other U.S. and international patents to which Ulthera, Inc. has rights are issued, published, or pending.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250409655489/en/

Contacts

Media Contact
Merz Aesthetics®
Global Corporate Communications
6501 Six Forks Road, Raleigh NC 27615
919-302-3296
media@merz.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fcts.businesswi
re.com%2Fct%2FCT%3Fid%3Dsmartlink%26url%3Dmailto%253A%252520media%2540merz.com%2
6esheet%3D54233560%26lan%3Den-US%26anchor%3Dmedia%2540merz.com%26index%3D3%26md5
%3D3235cfec4a5c30f18dfe762506c5dbc1&esheet=54233560&newsitemid=20250409655489&la
n=en-US&anchor=media%40merz.com&index=5&md5=1e3beed262b8f35333c21d285a109647

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye